SEP 228432

Drug Profile

SEP 228432

Alternative Names: SEP-225432

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Sepracor
  • Developer Sunovion Pharmaceuticals
  • Class Antidepressants
  • Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Phase I Major depressive disorder; Neuropathic pain
  • Discontinued Attention-deficit hyperactivity disorder

Most Recent Events

  • 29 Aug 2012 Sunovion Pharmaceuticals completes a phase I trial in healthy volunteers in USA (NCT01531972)
  • 10 Feb 2012 Sunovion Pharmaceuticals initiates enrolment in a Phase-I trial in healthy volunteers in USA (NCT01531972)
  • 29 Oct 2010 SEP 228432 is still in phase I development for Major depressive disorder in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top